Gelid®

Sodium Alginate BP & Potassium Bicarbonate BP
Chewable Tablet & Suspension

DESCRIPTION

Gelid® is a combined preparation of sodium alginate & potassium bicarbonate. This acts as an Anti-regurgitant agent. On ingestion the suspension or chewable tablet reacts with gastric acid to rapidly form a raft of alginic acid gel having a near-neutral pH which floats on the stomach contents effectively impeding gastro-oesophageal reflux for up to 4 hours, and protecting the oesophagus from acid, pepsin and bile. In severe cases the raft itself may be refluxed into the oesophagus in preference to the stomach contents and exert a demulcent effect. In addition in vitro evidence has shown that the raft has a secondary action and is able to entrap bile and pepsin within it structure, further protecting the oesophagus from these gastric components.

INDICATIONS

Treatment of symptoms resulting from the reflux of acid, bile and pepsin into the oesophagus such as acid regurgitation, heartburn, indigestion (occurring due to the reflux of stomach contents), for instance, after gastric surgery, as a result of hiatus hernia, during pregnancy, accompanying reflux oesophagitis, including symptoms of laryngopharyngeal reflux such as hoarseness and other voice disorders, sore throats and cough. Can also be used to treat the symptoms of gastro-oesophageal reflux during concomitant treatment with or following withdrawal of acid suppressing therapy.

DOSAGE & ADMINISTRATION

Chewable Tablet (The tablet must be chewed thoroughly before swallowing):

- **Adults and children 12 years and over:** One to two tablets after meals and at bedtime
- **Children under 12 years:** Should be given only on medical advice

Oral Suspension (Administered after meals and at bedtime):

- **Adults and children 12 years and over:** 5-10 mL
- **Children under 12 years:** Should be given only on medical advice

CONTRAINDICATIONS

Hypersensitivity to any of the ingredients.

SIDE EFFECTS

Very rarely patients may develop allergic manifestations such as urticaria or bronchospasm, anaphylactic or anaphylactoid reactions.

PRECAUTION & WARNING

Each 10 mL dose has a sodium content of 106 mg (4.6 mmol) and a potassium content of 78 mg (2.0 mmol). This should be taken into account when a highly restricted salt diet is recommended, e.g. in some cases of congestive cardiac failure and renal impairment or when taking drugs which can increase plasma potassium levels. Each 10 mL contains 200 mg (2.0 mmol) of calcium carbonate. Care needs to be taken in treating patients with hypercalcaemia, nephrocalcinosis and recurrent calcium containing renal calculi. There is a possibility of reduced efficacy in patients with very low levels of gastric acid. Treatment of children younger than 12 years of age is not generally recommended, except on medical advice. If symptoms do not improve after seven days, the clinical situation should be reviewed.

USE IN PREGNANCY & LACTATION

An open, uncontrolled study on pregnant women did not demonstrate any significant adverse effects of this suspension or chewable tablet on the course of pregnancy or on the health of the foetus/new-born child. Based on this and previous experience, this suspension or chewable tablet may be used during pregnancy and lactation.

PHARMACEUTICAL PRECAUTION

Do not store above 30 °C temperature. Keep away from light and wet place. Keep out of reach of children. Suspension should not be stored in refrigerator.

PACKAGING

Gelid® Chewable Tablet: Box containing 5 strips of 10 tablets each. Each tablet contains Sodium Alginate BP 500 mg & Potassium Bicarbonate BP 100 mg.

Gelid® Suspension: Bottle containing 200 mL of suspension. Each 5 mL contains Sodium Alginate BP 500 mg & Potassium Bicarbonate BP 100 mg.

SK+F
Manufactured by
ESKAYEF PHARMACEUTICALS LTD.
TONGI, GAZIPUR, BANGLADESH.

PM03396 V02